Focal segmental glomerulosclerosis as a rare side effect of combined anabolic-androgenic steroid use, high-protein diet and high-intensity anaerobic training
More details
Hide details
Collegium Medicum, Jan Kochanowski University in Kielce, Poland
Submission date: 2021-05-21
Final revision date: 2021-06-17
Acceptance date: 2021-06-18
Online publication date: 2021-09-01
Corresponding author
Andrzej Jaroszyński   

Collegium Medicum, Jan Kochanowski University in Kielce, IX Wieków Kielc 19A, 25-317 Kielce, Poland. Tel.: +48 604 968 724.
Pol. Ann. Med. 2022;29(2):226–228
Focal segmental glomerulosclerosis (FSGS) is a serious condition causing glomeruli damage and leading to nephrotic syndrome and renal failure. One of its causes is the prolonged use of anabolic-androgenic steroids (AAS), which has become a common trend among young athletes who are in a majority not aware of its side effects.

This study aimed to present an influence of performance-enhancing drugs (including AAS) combined with high-intensity training on renal failure, referring to a clinical case report.

Case study:
The study presents a 25-year-old male who was admitted to Nephrology Clinic with hematuria, proteinuria, elevated creatinine values, and hypertension. During hospitalization, a kidney biopsy was performed, which confirmed FSGS.

Results and discussion:
In our patient’s case, FSGS was caused by overusing performance-enhancing drugs (including AAS) for 10 years, a high-protein diet, and high-intensity training. When the patient had discontinued the use of all the performance-enhancing drugs and had begun appropriate treatment, the renal function parameters improved.

We conclude that overusing multiple performance-enhancing drugs may lead to renal failure and FSGS even in young adults with no congenital or immunological contributing factors. Thus such therapy should be disadvised especially to young athletes wanting to quickly improve their muscle mass.

None declared.
None declared.
Chou YH, Lien YC, Hu FC, et al. Clinical outcomes and predictors for ESRD and mortality in primary GN. Clin J Am Soc Nephrol. 2012;7(9):1401–1408.
Parkinson AB, Evans NA. Anabolic androgenic steroids: A survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644–651.
Pereira E, Moyses SJ, Ignácio SA, et al. Anabolic steroids among resistance training practitioners. PLoS One. 2019;14(10):e0223384.
van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117–123.
Eklo A, Thurelius A-M. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol. 2003;59:571–577.
Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V. Side effects of AAS abuse: An overview. Mini-Reviews Med Chem. 2011;11(5):374–389.
Herlitz LC, Markowitz GS, Farris AB, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol. 2010;21(1):163–172.
Daher EF, Silva Júnior GB, Queiroz AL, et al. Acute kidney injury due to anabolic steroid and vitamin supplement abuse: Report of two cases and a literature review. Int Urol Nephrol. 2009;41(3):717–723.
Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502–517.
Friedman AN. High-protein diets: Potential effects on the kidney in renal health and disease. Am J Kidney Dis. 2004;44(6):950–962.
Trumbo P, Schllicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002;102(11):1621–1630.
Hauger LE, Westlye LT, Fjell AM, Walhovd KB, Bjørnebekk A. Structural brain characteristics of anabolic–androgenic steroid dependence in men. Addiction. 2019;114(8):1405–1415.
Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep. 2002;4(5):377–387.